The evolution of negotiations of intangible assets apart from industrial property protection in biotechnology
Description
Mind Map on The evolution of negotiations of intangible assets apart from industrial property protection in biotechnology, created by Tatiana Suarez on 23/11/2018.
The evolution of negotiations of
intangible assets apart from industrial
property protection in biotechnology
STATE OF NEGOTIATIONS OF
INTAGIBLE ASSETS IN THE WORLD
In 1990’s was due to a boom in the negotiations of
intangible assets
Enterprise merging and acquisition,
using the IFRS3 [3] and FASB 141 [4]
standards as guidelines for their
valuation.
The former standard points
out the following restrictions:
Only acquired
intangibles are valued
Goodwill is often not
identified
Intangibles are
undervalued
The increased value of the
intangible assets is not
acknowledged
Some examples of
negotiations of intangible
assets
When Proctor and Gamble purchased Gillette in 63
billion dollars in 2005, the intangible assets were
valued in 55 billion dollars
Walt Disney paid 7.5 billion
dollars for the Pixar digital
animation studio.
In 2006, Google purchased
YouTube for 1.2 billion dollars,
which reached the headlines
of the brand stock exchange
THE INTANGIBLE STRENGTH OF THE
CUBAN BIOTECHONOLOGY INDUSTRY
Modern biotechnology, which arose and was developed
through the 1970’s and 1980’s, has been normally
established as coming from industrialized countries.
Novel products are
developed, which include
The preventive vaccine against
Neisseria meningitidis type b, with
patents granted in several countries
PPG, a unique product with
three patents granted
The vaccine against Haemophilus
influenzae type b, the only commercial
vaccine obtained by chemical synthesis
Heberprot-P®, a unique product with a
patent, with a demonstrated high
effectiveness in the treatment of diabetic
foot ulcers
been inspected by prestigious
regulatory authorities from
different countries
ECONOMIC IMPACT
Intangible assets in sectors with a
potential in intellectual property
leads to the proposal of the design of a
strategy
The intangible assets are a substantial
part of the economical benefits that a
biotech enterprise can receive, even
before a product is placed in the market